On June 12, Professor Erika Lietzan delivered a lecture on intellectual property in the life sciences sector as part of the WIPO-CPIP Summer School. This exclusive two-week summer course provides a deep dive into IP law and policy for students, professionals, and government officials from around the world. Professor Lietzan explained what makes intellectual property law and policy different in…
Tag: Drug Innovation ⋅ Page 1
Professor Lietzan speaks to Akron law students about perils of patent reform
At a recent event at the University of Akron School of Law, Professor Erika Lietzan spoke about what she called the “assault on drug patents,” including patent reform activity in Congress as well as proposals to prevent drug companies from patenting any changes or improvements to their drugs after approval (so called “one and done” proposals). She explained that medical…
Professor Lietzan’s Research Analyzes Patent Terms for New Medicine
A recent article in Bloomberg Law, U.S. Patent System Crimps Drug Innovation for Toughest Diseases, looks at the research of Professor Erika Lietzan and Kristina M.L. Acri about how the development of new drugs is affected by the U.S. patent system. Their research will be published in a forthcoming article. Their empirical research looked at 642 approved drugs to determine…
Symposium – Protecting the Public While Fostering Innovation and Entrepreneurship: First Principles for Optimal Regulation
In a one-day symposium, hosted by the law school’s Center for Intellectual Property & Entrepreneurship and Business, Entrepreneurship, and Tax Law Review, a distinguished group of panelists will consider both substantive principles for regulating effectively in particular areas (e.g., financial markets, telecommunications, prescription drugs, network technologies) and broader procedural questions about how regulations should be crafted. What substantive principles should guide…
Professor Lietzan Featured on Webcast about New Uses for Established Drugs
On March 29, Professor Erika Lietzan was the featured speaker in a webcast from the Syracuse College of Law’s IP Tech Law Center. She spoke with Shubha Ghosh about ensuring effective patent and regulatory exclusivity incentives for the development of new uses for already established drugs. Her recent article on this topic, “Paper Promises for Drug Innovation” will be published…
Erika Lietzan Featured on ‘The Week in Health Law’ Podcast
Professor Lietzan was recently a guest on “This Week in Health Law,” a commuting-length podcast that tackles thorny issues in health law and policy. She discussed her research on the relationship between drug innovation and incentives for innovation, and the conversation touched on large molecule drugs, biosimilars, data exclusivity and market exclusivity, patent protection, and her extensive empirical research on…